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ABSTRACT
Objective: To assess the impact of the 1997 Canadian guidelines on the
methods and presentation of economic evaluations conducted from a
Canadian perspective in the published literature.
Methods: A systematic literature review was conducted to identify health
technology economic evaluations conducted from a Canadian perspective
published in peer-reviewed journals between 2001 and 2006. To investi-
gate the impact of the 1997 Canadian Coordinating Ofﬁce of Health
Technology Assessment guidelines, each included study was assessed
against 17 of the 25 recommendations.
Results: Of the 153 included studies, a base set of 9 methodological
standards, as outlined by the 1997 guidelines, were followed by over 50%
of the studies including: indications, outcomes for cost utility analysis,
outcomes for cost beneﬁt analysis, discounting future cost and outcomes,
cost identiﬁcation and valuation, evaluating uncertainty and disclosing
funding relationships. Main divergences from the guidelines were found
for analytic technique (38%), study perspective (23%), source of prefer-
ences (8%), equity (7%), and cost measurement (24%).
Conclusion: The current assessment has shown that the 1997 Canadian
guidelines have set a minimum methodological standard within the
community of “doers” conducting economic analyses from a Canadian
perspective. Although there was divergence from some of the recommen-
dations, the majority were reﬂected as changes in the 2006 Canadian
guidelines.
Keywords: economic evaluation, guideline, health technology assessment.
Introduction
Economic evaluations of health technologies have become impor-
tant over the years as decision-making bodies are increasingly
including them as part of their evaluative process. They can be
used by various stakeholders (e.g., governments, public and
private insurers, institutions) to aid in decisions with respect to
reimbursement and research prioritization [1,2]. Due to their
potential impact on decision-making, there is a need for the
standardization of methodologies and reporting requirements of
economic evaluations.
In 1991, Ontario, a Canadian province, was the ﬁrst jurisdic-
tion to issue a draft set of guidelines for the economic evaluation
of pharmaceuticals. Australia followed in 1992 by adopting a set
of guidelines developed for drug formulary economic submis-
sions to the Pharmaceutical Beneﬁts Advisory Committee [3].
The Ontario draft guidelines were highly inﬂuential in the devel-
opment of the ﬁrst set of Canadian guidelines. Over the past two
decades, a number of other countries [4] have implemented their
own set of guidelines which either act as guidelines for formulary
submissions or for the conduct of economic evaluations [5].
In Canada, three editions of the guidelines have been pub-
lished. The ﬁrst two editions were published in 1994 [6] and 1997
[7] by the Canadian Coordinating Ofﬁce for Health Technology
Assessment (CCOHTA), which became the Canadian Agency for
Drugs and Technologies in Health (CADTH) in April 2006. In an
effort to reﬂect the new orientation of CADTH, the third edition
of the guidelines, published in 2006 was directed towards all
health technologies including nondrug technologies [8].
While CADTH continues to update and recommend methods
for the conduct of economic evaluations in Canada, it is impor-
tant to understand whether the previous editions of the guide-
lines have had an impact on the community of researchers that
conduct economic evaluations in Canada. The two previous
articles evaluating the impact of the 1994 Canadian guidelines
were based on a sample of 12 economic evaluations submitted to
CCOHTA between 1995 and 1996 [9] and 21 submissions to the
British Columbia Pharmacoeconomics Initiative Scientiﬁc Com-
mittee in 1996, respectively [10]. Both articles indicated that
while the studies met a minimum set of standards, several rec-
ommendations were not followed (e.g., utility measurement,
reporting of resource utilization or costing, choice of compara-
tors or discounting) [9,10].
The limited alignment of the economic evaluations with the
ﬁrst edition of the Canadian guidelines may be misleading as the
samples of these two studies were taken only 1 to 2 years after
the release of the guidelines,whichmay not have allowed sufﬁcient
time for the uptake of the guidelines. Nevertheless, Anis et al. [11]
analyzed 95 submissions conducted between 1996 and 1999,
against the 1994 guidelines, where similar results were observed.
The assessment of Canadian economic evaluations against the
1997 edition of the guidelines however has not been conducted. To
provide an update to previouswork, this study set out to assess the
impact of the 1997 Canadian guidelines on the methods and
presentation of economic evaluations by evaluating Canadian
economic evaluations published between 2001 and 2006.
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Methods
Literature Search
A search strategy was developed to identify the published peer-
reviewed literature evaluating economic evaluations of health
technologies in Canada. Individualized search strategies for each
electronic database using relevant subject headings were created
accompanied by the use of the following keywords: Canada,
economic evaluation, cost beneﬁt analysis (CBA), cost minimi-
zation analysis (CMA), cost-effectiveness analysis (CEA), cost
utility analysis (CUA), and cost consequence. The search was
limited to English and French language literature published
between January 2001 and June 2006. The primary computer-
ized search was conducted by cross-searching OVID MED-
LINE®, and EMBASE, CINAHL, Health Economic Evaluations
Database (OHE HEED), Canadian Research Index, and Centre
for Review and Dissemination which includes Database of
Abstracts of Reviews of Effects, National Health Services, Eco-
nomic Evaluations Database, and Health Technology Assessment
databases.
Study Selection
Included studies examined both the costs and outcomes associ-
ated with health-care technologies or programs from a Canadian
perspective including studies that were Canadianized (i.e.,
Canadian inputs were used in a model originally developed for
another country). Studies using either decision analytic models
and/or patient level analyses were examined. Excluded articles
were efﬁcacy or effectiveness studies, costing-only studies, studies
performed from a non-Canadian perspective, health technology
assessment reports that were not published, methodological
articles, letters, commentaries, reviews, and those not analyzing
a health issue. One reviewer, using predetermined inclusion/
exclusion criteria, screened titles and abstracts of identiﬁed
studies. Consensus with a second reviewer was obtained when it
was uncertain if a study met the inclusion criteria. Full text
versions of the published articles were obtained for those studies
that met the inclusion criteria and also for those studies where
suitability for the review could not be determined based on the
title and abstract. The same criteria were used in the full text
review to include/exclude articles with the exception of articles
presenting only a cost-consequence analysis (CCA), which were
excluded from the ﬁnal sample of studies. This choice is aligned
with the recommendations of the 1997 guidelines which indicate
a CCA is acceptable when clinical outcomes between two inter-
ventions differ, however, needs to be accompanied by a CEA, a
CUA, or a CBA. For this reason, when a study included a CCA
and either a CEA, CUA or CBA, we classiﬁed this study as a
CEA, CUA, or CBA. In addition, CCAs have to ﬁrst be con-
ducted to complete a CEA, CUA, or CBA, therefore, all studies
could be considered CCAs. As a result, we did not include studies
presenting only a CCA in the ﬁnal sample and evaluated only
CMAs, CEAs, CUAs, and CBAs. A bibliographic search of the
included studies was also completed to ensure that all relevant
studies were identiﬁed.
Guidelines Assessment
The 1997 Canadian guidelines included a total of 25 recommen-
dations for conducting an economic evaluation, study design and
results reporting. As the guidelines were not meant to be pre-
scriptive and some of the recommendations are dependent on a
variable list of factors unique to each study, only 17 of the
recommendations were assessed. The included recommendations
were those assessed in Baladi et al. [9] and those that could be
objectively assessed. For example, the ﬁrst three recommenda-
tions of the guidelines touched on general study aspects (i.e.,
target audience of the report, timing, and management of study)
and as such were not assessed. Other recommendations (i.e.,
listing of all assumptions, detailed reporting of results) were
excluded based on the difﬁculty to generalize results in the
context of publication (i.e., space limitation). As only CMA,
CBA, CUA, and CEAs were included, costs and effects were
always reported as increment. As such, all studies complied with
the recommendation related to incremental and total analysis.
Health-related quality of life is only relevant for prospective
studies and therefore was not assessed. Portability of results was
not included because transferability of results is dependent on the
local setting being evaluated.
Table 1 presents a description of all 25 guideline recommen-
dations and itemizes the rationale for exclusion. They were
evaluated against the recommended base case analysis. For
example, the guidelines state a societal perspective should be
used for the base case analysis. Therefore, if a study did not
present a societal perspective, it would be categorized as inap-
propriate. Additionally, because of the methodological uncer-
tainty around some of the recommendations, some interpretation
was necessary. For example, the guidelines indicated a preference
for a CUA or a CBA because they allow comparisons between
different interventions. While a CEA may be justiﬁable in some
cases, we interpreted the use of a CUA or CBA to be prescriptive.
Three recommendations (comparators, time horizon, and
effectiveness) requiring in-depth knowledge of the disease were
evaluated using proxies and therefore not included in the overall
impact assessment. The guidelines recommended comparing the
new intervention against both existing and minimum practice. As
a proxy for appropriate treatment, we captured if the compara-
tor was an active treatment, placebo, or do-nothing or wait and
see alternative. The time horizon was documented as short term
(<1 year) or long term (>1 year) and effectiveness was evaluated
based on the source of evidence. To accurately evaluate the use of
effectiveness versus efﬁcacy data would have meant being famil-
iar with every source cited. Instead, we captured the types of
sources of evidence as an appreciation of the quality of the
clinical evidence. Table 1 summarizes this information.
Data Abstraction and Analysis
To investigate whether economic evaluations published between
January 2001 and June 2006 from a Canadian perspective fol-
lowed the 1997 CCOHTA guidelines; each study was assessed
against a total of 17 recommendations (Table 1). Based on these
17 recommendations, an abstraction form was created: analytic
technique, indications, treatment comparators, perspective, ana-
lytic horizon, efﬁcacy/effectiveness data, outcomes, resource uti-
lization, costing, methods to deal with uncertainty, equity, and
funding disclosure. A draft abstraction form was piloted with 15
studies to ensure that the proper data were recorded and that the
form minimized data interpretation. The studies and the data
abstracted for these 15 studies were reviewed by a second
reviewer and the abstraction form was modiﬁed to accommodate
any comments regarding data capture or interpretation. Once the
form was ﬁnalized, one reviewer abstracted all identiﬁed publi-
cations. Consensus with a second reviewer was obtained during
the data abstraction phase when there were doubts. At the end of
the data collection phase, a second reviewer independently
assessed a 15% random sample of the studies. There was 100%
agreement with all 17 recommendations. A Microsoft® Access
database was developed to enter and analyze the data.
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Results
Systematic Literature Review
The literature search, completed on June 16, 2006, identiﬁed
1743 unique citations following the removal of duplicates. After
screening titles and abstracts, 1420 citations were excluded,
mainly because they were not an economic evaluation or a full
journal article (e.g., letter). A full text review of the remaining
323 articles resulted in the exclusion of 170 citations, resulting in
a ﬁnal sample of 153 studies. A summary of the details of the
study selection process is outlined in Figure 1.
Study Descriptions
The review process identiﬁed 153 Canadian economic evalua-
tions published between January 2001 and June 2006. The col-
lected studies represent a diverse group of health technologies.
The technologies evaluated included drugs (49%), devices
(12%), procedures (14%), programs (12%), and other (3%).
The remaining 10% of the studies evaluated a combination of
technologies (e.g., vaccination program). Of the 138 evaluations
which identiﬁed sources of funding, 54% of funding was from
industry and the rest were evenly distributed among academic
granting agencies (17%), disease-related organizations or foun-
dations (12%), government (12%), and other (4%).
Impact of the 1997 CCOHTA Guidelines
The following section presents the results of the impact assess-
ment of the 17 recommendations from the 1997 guidelines
described in the methods section (Table 2).
Analytic technique. Of the identiﬁed studies 18% used a CUA
and 16% conducted both a CUA and CEA resulting in 34% of
the studies using CUA as a method of evaluation. In comparison,
over half of the studies (58%) used a CEA framework. A minimal
number of CMA and CBA reports were identiﬁed representing
4% and 3% of the studies, respectively.
Indications. In almost all of the studies evaluated (96%), the
target population was clearly identiﬁed.
Table 1 Recommendations of the 1997 Canadian Coordinating Ofﬁce for Health Technology Assessment guidelines and rationale for exclusion
Recommendation Included* Reason for exclusion
Target audience Identify the primary target audience No Nonmethodological
Timing of studies Timing in the product life-cycle. No Requires expertise on the life-cycle of a product.
Management of studies Was a protocol written? Who conducted the economic
evaluation? How was it disseminated?
No Involves contacting the lead author of each study to
inquire about its management.
Incremental and total analysis Costs and effects must be reported as increments. No Cost-consequence analyses were excluded and therefore
all costs and effects were reported as increments.
Analytic technique Cost-consequence analysis plus one or more of
cost-effectiveness, cost-beneﬁt or cost-utility analysis.
Cost-beneﬁt and cost-utility analyses are preferred.
Yes N/A
Indications Identify the target population Yes N/A
Treatment comparator Compare against both existing and minimum practice Yes* Captured if the comparator was an active treatment,
placebo, or do-nothing alternative.
Perspective Societal Yes N/A
Analytic horizon Long enough to capture all relevant outcomes Yes* Captured if the time horizon was short-term (<1 year)
or long-term (>1 year).
Assumptions Include a comprehensive list of assumptions used for
the analysis
No Limited by publication space.
Efﬁcacy vs. effectiveness Effectiveness rather than efﬁcacy Yes* Captured whether the source of evidence was efﬁcacy
(randomized controlled trial) or effectiveness
(observational study or expert opinion).
Health-related quality of life For a prospective study including HRQOL, advised to
use an instrument from each of the following: speciﬁc
measures, general proﬁle and preference based
measures
No Only relevant for prospective studies.
Outcomes for CUA Use quality adjusted life years Yes N/A
Outcomes for CBA Use of contingent valuation preferred Yes N/A
Source of preferences Public preferences (public good proxy) Yes N/A
Equity Equal weights for all Yes N/A
Discounting future outcomes If time horizon is greater than 1 year then use a 5%
discount rate
Yes N/A
Cost identiﬁcation Identify all relevant resource items. Use the human
capital approach to measure indirect costs
Yes N/A
Cost measurement (resource
use)
Include natural units of resources used Yes N/A
Cost valuation (unit prices) Include unit prices Yes N/A
Discounting future costs If time horizon is greater than 1 year then use a 5%
discount rate
Yes N/A
Dealing with uncertainty Deterministic or probabilistic sensitivity analysis Yes N/A
Reporting results Report results in a clear and transparent manner.
Should present disaggregated detail ﬁrst then
aggregated. Should present diagrams if modeling.
No It is possible to report results in a variety of ways
depending on the methods used (e.g., model vs.
patient level data, CUA vs. CBA).
Portability of economic
evaluations
Distinction between efﬁcacy and effectiveness and
validity of transferring results from one setting to
another.
No This is partially assessed when evaluating whether efﬁcacy
or effectiveness measures were used.Transferability of
results is dependent on the local setting under
consideration, therefore, cannot be assessed.
Disclosure of relationships Funding and reporting relationships must be clearly
described
Yes N/A
*Indicates recommendations that were not included in the overall impact assessment because proxy measures were used.
HRQOL, health-related quality of life; CUA, cost utility analysis; CBA, cost beneﬁt analysis.
330 Lim et al.
Comparators. In the 153 studies, 213 comparators were evalu-
ated where 74% were considered an active treatment (device,
procedure, program, other), 9% were placebos, and 17% were
“do nothing” or “wait and see.”
Perspective. The guidelines advise the use of a societal perspec-
tive for the base case analysis. The government perspective
(48%) was the most commonly used base case analysis. The
societal perspective and third payer perspective were used 23%
and 15%, respectively. Of those who used multiple perspec-
tives (n = 26) 42% used the societal perspective for a secondary
analysis.
Time horizon. Approximately 76% (n = 116) of studies stated a
time horizon. Of these, 15% used lifetime and 44% used a time
horizon greater than 1 year. Overall, 41% used a time horizon of
less than 1 year and only a few studies presented multiple time
horizons.
Effectiveness/sources of evidence. There were 273 sources of
evidence used in the 153 studies. Data derived from trials—
individual trials (51%) and meta-analyses (10%)—together com-
prised efﬁcacy sources (61%). All other sources were classiﬁed as
effectiveness sources (39%): literature reviews (11%), expert
opinion (8%), administrative databases (5%), and other (15%).
Fifty-one percent of the studies used evidence based on a single
source (e.g., one clinical trial).
Outcomes for CUA. Of the 52 CUA studies, 94% used quality
adjusted life years (QALYs), whereas the remainder used quality
adjusted disease speciﬁc outcomes (e.g., quality adjusted progres-
sion free years gained).
Outcomes for CBA. Of the six CBA studies, 50% used contin-
gent valuation to elicit willingness-to-pay values.
Source of preferences. Forty-eight percent of the 52 CUA studies
sampled patients to derive utilities, 8% sampled the general
public, 13% sampled clinicians, 2% used utilities derived from
published articles, and 29% were unclear as to where the utilities
were derived (e.g., reference to an article but without stating the
methods).
Equity. Seven percent of studies addressed distributional
considerations.
Costing. Ninety-seven percent of studies identiﬁed resources for
costing. Seventy-eight percent indicated the sources of cost data
and 52% presented unit costs. Seventy-three percent indicated
the year of currency. Of the 338 sources reported, the majority of
unit costs were derived from provincial formularies (29%), other
studies (18%), and administrative databases (16%).
Twenty-eight percent (n = 43) of studies included indirect
costs. Of these studies, 23% (n = 10) used the human capital
approach, 37% (n = 16) used a replacement cost method and
40% (n = 17) did not report the method used for measuring
indirect costs.
Twenty-four percent of studies reported results for resource
utilization in a table. Fifty-one percent of studies stated that they
used resources that were Canadian or from Canadian sources,
where 14% used resources from other countries. It was unclear
whether the source of resource utilization was Canadian in
approximately 35% of reports.
Discounting. Eighty-six percent of studies with a time horizon
greater than 1 year included discounting. Of the studies that
Potentially relevant citations identified and 
screened by title and abstract (n=1743) 
Citations excluded based on title and abstract (n=1420) 
•Not a full report (n=563) 
•Not an Economic Evaluation (n=678) 
•Cost study (n=286) 
•Outcome (n=47) 
•Methodology (n=104) 
•Other (n=241) 
•Not Canadian (n=142) 
•Not a health study (n=6) 
•Language (n=8) 
•Technology report / HTA (n=23)  Citations retrieved for full text review (n=323) 
Citations excluded based on full text review 
(n=170)
•Not a full report (n=19) 
•Not an Economic Evaluation (n=115) 
•Cost study (n=14) 
•Outcome (n=7) 
•Methodology (n=5) 
•Cost consequence analysis (n=77) 
•Other (n=12) 
•Not Canadian (n=31) 
•Not a health study (n=5)
Citations included in review (n=153) 
2001 n=23 
2002 n=27 
2003 n=36 
2004 n=38 
2005 n=23 
2006 n=6 
Figure 1 QUORUM diagram of included and excluded studies from the systematic literature review.
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included discounting (n = 68), 97% discounted costs and 84%
discounted outcomes. Forty-seven percent of the studies dis-
counting costs used a 5% discount rate and 44% of the studies
discounting outcomes used a 5% discount rate as recommended
by the guidelines.
Uncertainty. Of the 153 studies, 90% conducted a deterministic
univariate or multi-way sensitivity analysis (SA). Approximately,
28% plotted variability and uncertainty, which includes both
Monte Carlo and any plotted SA. Of the studies with patient
level data, 26% attempted to deal with incremental cost-
effectiveness ratio (ICER) uncertainty, where bootstrapping was
the only method used. The majority of studies (67%) performed
a deterministic one-way univariate analysis, 17% performed a
deterministic multi-way analysis and 26% performed a probabi-
listic SA.
Disclosure of relationships. Ninety percent (n = 138) of studies
reported the source of funding.
Overall impact. Figure 2 presents the percentage of studies that
followed 14 of the recommendations (comparators, time horizon
and efﬁcacy vs. effectiveness were excluded). The denominators
varied depending on the guideline (e.g., discounting was calcu-
lated from the studies [n = 68] that reported a time horizon
greater than 1 year). Main divergences from the guidelines were
found for analytic technique (38%), study perspective (23%),
source of preferences (8%), equity (7%), and cost measurement
(24%). Over 50% of studies followed nine of the recommenda-
tions, with 90% or greater of studies using the following guide-
lines: indications, outcomes for CUA, cost identiﬁcation,
discounting costs, assessing uncertainty, and disclosing funding
relationships.
Discussion
Guidelines for the conduct of economic evaluations have gained
signiﬁcant recognition over the past couple of decades. This is
evidenced by the increasing number of countries adopting the use
of their own set of guidelines [4]. To date, there have been three
versions of the Canadian guidelines: the ﬁrst edition in 1994, the
second in 1997, and the third in 2006. Initially, the national
guidelines were developed so that each province could adopt
them, with or without modiﬁcation, into their submission
process [7]. Subsequently, the Common Drug Review was
created in 2003 to harmonize the drug reimbursement submis-
sion process across Canada, where submissions are required to
have an economic evaluation and recommended to follow the
guidelines. In addition to guiding economic evaluations of drug
submissions, the Canadian guidelines are transferable to the
evaluation of any health technology and therefore to a variety of
“doers” (e.g., academia and government). The guidelines are
meant to be as prescriptive as possible but ﬂexible enough to
provide opportunities for creativity and innovation [7]. They
represent insights from government, academia, industry, and
health-care professionals and are a combination of both new
methodology and “the standard” at the time of inception [7].
They are meant to be methodological guidelines and there is no
policy in Canada requiring compliance. Therefore, given the
context within which the guidelines are applied, the purpose of
this study was to assess the impact of the 1997 Canadian guide-
lines on the research community.
Our results are based on a large sample of published eco-
nomic evaluations and showed that describing indications,
choosing appropriate outcomes (i.e., QALYs and contingent
valuation), analyzing uncertainty, discounting, and costing were
fairly consistent with the recommendations. Although studies
were consistent in reporting the resources used and their prices,
only a quarter of the studies included the natural units. Almost
all studies discounted outcomes and costs if they used a time
horizon greater than one year. Major divergences were evident
for the analytic technique, study perspective, source of preference
elicitation for quality of life, and discussion of equity. It is not
surprising to ﬁnd divergence from these recommendations as
these mostly reﬂect pragmatic solutions or necessary method-
ological variations based on the disease or technology under
evaluation. For instance, if a hospital commissions an economic
evaluation, they will most likely be interested in only resources
that directly affect their budget. Additionally, conducting an
economic evaluation from a societal perspective can be difﬁcult
because of data limitations and disproportionate views on how
to calculate indirect costs. More speciﬁcally, the 1997 guidelines
encourage the use of the human capital approach whereas at the
time a breadth of literature exists debating the appropriate
methods of measuring indirect costs (human capital approach vs.
friction cost method vs. willingness-to-pay) [12–14]. Similarly,
the evaluation depends signiﬁcantly on the technology under
evaluation. For instance, a CUA may be inappropriate when
evaluating a diagnostic technology where users may be more
interested in diagnostic accuracy outcomes (e.g., sensitivity and
speciﬁcity). The minimal discussion of equity within the studies
was expected as authors most likely rely on an implicit assump-
tion of equal weights. Equity considerations are important as the
results could impact various jurisdictions and subgroups in
Table 2 Percentage of studies following 17 recommendations from
1997 CCOHTA guidelines
Recommendation n (%)
Analytic technique (n = 153) CEA 89 (58)
CUA 28 (18)
CBA 5 (3)
CMA 6 (4)
CEA and CUA 24 (16)
CEA and CBA 1 (1)
Indications (n = 153) Target population identiﬁed 147 (96)
Comparators (n = 213) Active treatment 157 (74)
Placebo 19 (9)
Do nothing or wait and see 37 (17)
Study perspective (n = 129) Societal 30 (23)
Government 62 (48)
Patient 0
Hospital 8 (6)
Third party payer 19 (15)
Other 10 (8)
Time horizon (n = 116) Short term 48 (41)
Long term (>1 year and lifetime) 68 (59)
Effectiveness (n = 273) Used effectiveness 106 (39)
Outcomes for CUA (n = 52) QALY 49 (94)
Outcomes for CBA (n = 6) Contingent valuation 3 (50)
Source of preference (n = 52) Public preference 4 (8)
Equity (n = 153) Equal weights for all 11 (7)
Cost identiﬁcation (n = 153) Individual resource items identiﬁed
148 (97)
Cost measurement (n = 153) Quantity of physical resources 37 (24)
Resources Canadian? 78 (51)
Cost valuation (n = 153) Unit prices 80 (52)
Discounting future outcomes
(n = 68)
If time horizon >1 year 57 (84)
Discounting future costs (n = 68) If time horizon >1 year 66 (97)
Uncertainty (n = 153) Deterministic or probabilistic 138 (90)
Disclosure of relationships
(n = 153)
Funding reported 138 (90)
CEA, cost-effectiveness analysis; CUA, cost utility analysis; CBA, cost beneﬁt analysis; CMA,
cost minimization analysis; QALY, quality adjusted life year.
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Canada [9] and are essential for decision-makers who are con-
cerned with the redistribution of resources in various sectors in
society [8]. The most notable divergence is the source of prefer-
ences. The guidelines are quite prescriptive in their recommen-
dation for the use of informed general public preferences.
Several limitations were associated with this study. First, only
the published literature was evaluated which may not fully reﬂect
the spectrum of economic evaluations conducted from a Cana-
dian perspective. A full representation would have also included
drug submissions and health technology assessment reports.
Nevertheless, drug submissions are not accessible to the public
and health technology assessments are not always published. For
more information on economic evaluations conducted by Cana-
dian HTA agencies, the reader is referred to Tarride et al. [15].
Second, because of the broad research question and the chal-
lenges associated with developing a literature search strategy that
includes all relevant studies, there was a risk that some studies
may have been missed in the initial screening process or not
identiﬁed. To minimize this risk, the references listed in the
included studies were manually searched to identify potential
missed studies. There is also a risk that some study characteristics
may have been misclassiﬁed despite our attempts to develop a
questionnaire requiring minimal data interpretation. Addition-
ally, there is a strong possibility that several key methodological
issues were not described because of publication space limita-
tions. Alternatively, some journals allow the use of electronic
appendices, which only a few studies utilized. Lastly, although a
random sample of studies was checked by a second reviewer, one
person screened and abstracted the data. In spite of these limita-
tions, the results are based on a large sample of economic evalu-
ations conducted from a Canadian perspective providing a
reliable assessment of the impact of the 1997 guidelines. Given
the circumstances in which the Canadian guidelines are applied,
a minimum set of standards was evident.
Some of the divergences noted in the results are aligned with
changes in the 2006 edition of the Canadian guidelines. There are
three signiﬁcant changes in methodology between the 1997 and
2006 CADTH guidelines for the economic evaluation of health
technologies. The 2006 guidelines now recommend: 1) using a
CUA when health-related quality of life is a signiﬁcant outcome
or a CEA when CUA is inappropriate, whereas the 1997 guide-
lines recommend a CUA or CBA; 2) using a publicly funded
health-care system perspective over that of societal; and 3) it is
now preferred to use the friction cost method as opposed to the
human capital approach recommended in the 1997 guidelines.
There was also discussion around certain issues in the 1997
edition that were clariﬁed in the 2006 edition. Although the 2006
edition still advocates the use of a CMA under certain conditions
(e.g., equivalence trial) it strongly emphasizes the use of proba-
bilistic SA before using this evaluation method. When eliciting
direct preferences, the guidelines now recommend avoiding the
use of visual analog scale and instead only using standard gamble
(SG) or time trade-off (TTO). They also strongly emphasize the
use of a probabilistic SA and a Monte Carlo simulation. Lastly,
they now recommend including all assumptions on equity and
discussing their relevance on the results instead of only including
equal weights and allowing the decision-maker to apply different
weights.
Figure 2 Adherence to the 1997 Canadian Coordinating Ofﬁce for Health Technology Assessment guidelines.
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Barriers associated with implementing the guidelines may
include: lack of access to data, poor quality of evidence, absence
of real-world effectiveness or the expertise in how to interpret the
information and economic evaluation training. Further barriers
may exist between decision-makers and their use of economic
evaluations, which may also limit the full adoption of the Cana-
dian guidelines. In addition to the lack of training in health
economics [16], decision-makers are resistant towards the uptake
of economic evidence because they, among other reasons, believe
that economic evaluations seek to simplify complex questions
into a single number (i.e., ICER) and are used to justify budget
expansions based on threshold analysis [2].
Conclusion
The current assessment has shown that the 1997 Canadian
guidelines have contributed to a minimum set of methodological
standards used within the community of “doers” conducting
economic analyses from a Canadian perspective. Although there
was divergence from some of the recommendations, the majority
were reﬂected as changes in the 2006 Canadian guidelines. In
light of recent methodological advances and an increasing
number of researchers trained in the conduct of economic evalu-
ations, it would be beneﬁcial to monitor the impact of the 2006
Canadian guidelines.
Source of ﬁnancial support: This research was funded by a 2006 Capacity
Building Grant from the Canadian Agency for Drugs and Technologies in
Health.
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